Table 1.
Baseline characteristics in the unmatched cohorts and propensity score matched cohorts among patients with hyperuricaemia
| Unmatched* cohorts | Propensity score matched cohorts | |||
|---|---|---|---|---|
| Baseline characteristics | Allopurinol initiators (N=6587) |
Non-initiators (N=6587) |
Allopurinol initiators (N=5927) |
Non-initiators (N=5927) |
| Demographics | ||||
| Age, years | 67.5 | 66.8 | 67.4 | 67.6 |
| Male, % | 70 | 59 | 69 | 72 |
| BMI, kg/m2 | 30.2 | 29.6 | 30.1 | 30.0 |
| Measures of comorbidity | ||||
| Charlson index, mean | 1.0 | 0.8 | 0.9 | 0.9 |
| Hypertension, % | 67.7 | 67.6 | 67.0 | 69.5 |
| Stroke, % | 10.9 | 9.4 | 10.5 | 11.9 |
| Myocardial infarction, % | 1.9 | 1.6 | 1.8 | 1.9 |
| Diabetes, % | 14.8 | 14.4 | 14.1 | 14.5 |
| Gout, % | 85.4 | 30.0 | 83.7 | 84.4 |
| Primary care visits, N | 12.4 | 11.0 | 12.3 | 11.8 |
| Medications | ||||
| Statin, % | 57.8 | 50.9 | 57.0 | 54.6 |
| Fibrate, % | 2.7 | 2.5 | 2.6 | 2.3 |
| ACE inhibitors, % | 52.0 | 45.6 | 50.9 | 50.1 |
| ARBs, % | 15.8 | 12.6 | 15.2 | 14.6 |
| β-blockers, % | 44.8 | 38.1 | 43.9 | 44.0 |
| Calcium channel blockers, % | 35.5 | 35.7 | 35.8 | 36.5 |
| Aspirin, % | 42.8 | 38.2 | 41.8 | 42.2 |
| NSAIDs, % | 73.9 | 49.9 | 73.0 | 75.4 |
| Loop diuretics, % | 36.3 | 20.2 | 34.0 | 31.1 |
| Hydrochlorothiazide, % | 36.1 | 40.3 | 36.7 | 37.3 |
| Losartan, % | 4.0 | 4.3 | 4.0 | 4.5 |
| Insulin, % | 4.4 | 3.3 | 4.0 | 3.8 |
| Laboratory measurements (baseline) | ||||
| Serum uric acid, µmol/L | 531 | 442 | 522 | 519 |
| Albumin, mmol/L | 41.9 | 42.2 | 41.9 | 42.1 |
| GFR, mL/min per 1.73 m2 | 59.26 | 64.68 | 60.01 | 61.00 |
| Cholesterol, mmol/L | 4.93 | 5.06 | 4.95 | 4.95 |
*
A non-initiator was randomly selected for each initiator (without propensity score matching) within each 6-month cohort accrual block.
ARB, angiotensin receptor blocker; BMI, body mass index; GFR, glomerular filtration rate; NSAID, non-steroidal anti-inflammatory drug.